Allogene Therapeutics, Inc. (ALLO)
About Allogene Therapeutics, Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $0
- Net income
- -$190.9M
- Total assets
- $415.9M
- Market cap
- $648.9M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $209.3M
- Operating income
- -$209.3M
- Income tax
- $0
- Net income
- -$190.9M
- EPS (basic)
- $-0.87
- EPS (diluted)
- $-0.87
Balance sheet
- Total assets
- $415.9M
- Current assets
- $257.7M
- Total liabilities
- $123.4M
- Current liabilities
- $32.5M
- Shareholders’ equity
- $292.5M
Cash flow
- Operating cash flow
- -$149.2M
- Investing cash flow
- $95.6M
- Financing cash flow
- $30.2M
- Net cash flow
- -$23.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $648.9M
- EPS (diluted)
- $-0.87
- Shares outstanding
- 372.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 11, 2018
Allogene Therapeutics, Inc. (ALLO) Stock Price
- Reported a net loss of $190.9M in FY2025.
- Trading 43% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Allogene Therapeutics, Inc..
Write a review
News about Allogene Therapeutics, Inc.
News & sentiment via Polygon.io
Allogene Therapeutics, Inc.: frequently asked questions
Is Allogene Therapeutics, Inc. an American company?
Allogene Therapeutics, Inc. is a US-based company headquartered in South San Francisco, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Allogene Therapeutics, Inc. headquartered?
Allogene Therapeutics, Inc. is headquartered in South San Francisco, California, United States.
Is Allogene Therapeutics, Inc. publicly traded?
Yes — Allogene Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol ALLO on the NASDAQ.
What does Allogene Therapeutics, Inc. do?
Allogene Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
